Ledraxen

Enoxaparin Sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous, intravenous and haemodialysis use. It is employed to prevent and treat venous thromboembolic disorders and to provide anticoagulation during renal replacement therapy.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ledraxen, a low molecular weight heparin, acts on the coagulation cascade to reduce clot formation in several clinical settings.

- Venous thromboembolism prophylaxis: Reduces the risk of deep‑vein thrombosis and pulmonary embolism in surgical and medically immobilised patients. - Deep‑vein thrombosis and pulmonary embolism treatment: Facilitates clot resolution and prevents extension of existing thrombi. - Anticoagulation during haemodialysis: Provides safe anticoagulation to maintain circuit patency without excessive bleeding.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects: - Injection site pain or bruising: Local discomfort at the administration site. - Minor bleeding: Nosebleeds, gum bleeding, or easy bruising. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Major bleeding: Intracranial, gastrointestinal or retroperitoneal hemorrhage. - Heparin‑induced thrombocytopenia (HIT): Immune‑mediated platelet decline with paradoxical thrombosis. - Spinal or epidural hematoma: Bleeding in the spinal canal after neuraxial procedures. - Severe allergic reaction: Anaphylaxis, urticaria or angioedema.

Careful assessment and monitoring are required when using Ledraxen.

- Renal impairment: Adjust dose or monitor anti‑Xa activity in patients with reduced kidney function. - Surgery or invasive procedures: Discontinue before the procedure to minimise bleeding risk. - Concomitant anticoagulants: Avoid or closely monitor when used with other anticoagulant agents. - Antiplatelet therapy: Use with caution together with aspirin, clopidogrel or similar drugs. - Pregnancy and lactation: Reserve for situations where benefit outweighs potential fetal or neonatal risk. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin may interact with several drug classes, altering its safety profile.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct thrombin inhibitors). - Combination with antiplatelet agents such as aspirin or clopidogrel. - Co‑administration with fibrinolytic therapy (e.g., alteplase).

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding tendency. - Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents. - Renally cleared drugs (e.g., aminoglycosides) that may affect enoxaparin clearance.